Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor. 2002

Gadi Borkow, and Horacio Salomon, and Mark A Wainberg, and Michael A Parniak
Lady Davis Institute for Medical Research, McGill University AIDS Centre, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada.

Short exposure of uninfected lymphocytes to UC781, a tight-binding nonnucleoside reverse transcriptase inhibitor (NNRTI), renders these cells refractory to subsequent HIV infection in the absence of exogenous drug (Borkow et al: J Virol 1997;71:3023-3030). Since epithelial cells may play a role in the sexual transmission of HIV-1, we examined the ability of NNRTI pretreatment to protect ME180 cervical epithelial cells and I407 intestinal epithelial cells from subsequent HIV-1 infection. Epithelial cells were pretreated with NNRTI, then exposed to HIV-1 chronically infected H9(+) cells for a short time following removal of the exogenous drug. The epithelial cells were productively infected by HIV-1, as shown by the presence of integrated HIV-1 proviral DNA, the presence of intracellular p24 antigen, and the production of nascent HIV-1 virions (cell-free p24) at various times postinfection. UC781 pretreatment of the epithelial cells did not prevent HIV-1 infection, since the cells had integrated proviral DNA, but the infectivity of virus subsequently produced from the UC781-treated cells was attenuated in a dose-dependent manner and virtually abolished at UC781 concentrations readily attainable in vivo. In contrast, nevirapine was ineffective in this respect, suggesting that not all NNRTI have microbicidal potential. The abrogation of infectivity of virus produced from UC781-pretreated epithelial cells suggests that this NNRTI may be useful in vaginal microbicide formulations targeted to inhibit HIV-1 in the vaginal/cervical or rectal milieus of a newly exposed individual.

UI MeSH Term Description Entries
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002584 Cervix Uteri The neck portion of the UTERUS between the lower isthmus and the VAGINA forming the cervical canal. Cervical Canal of the Uterus,Cervical Canal, Uterine,Ectocervix,Endocervical Canal,Endocervix,External Os Cervix,External Os of the Cervix,Uterine Cervical Canal,Cervix,Cervixes,Uterine Cervix,Canal, Endocervical,Canal, Uterine Cervical,Cervix, External Os,Cervix, Uterine,Endocervical Canals,Uterine Cervical Canals
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005663 Furans Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Tetrahydrofurans
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000813 Anilides Any aromatic amide obtained by acylation of aniline.
D013854 Thioamides Organic compounds containing the radical -CSNH2. Thioamide
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse

Related Publications

Gadi Borkow, and Horacio Salomon, and Mark A Wainberg, and Michael A Parniak
June 1997, Biochemistry,
Gadi Borkow, and Horacio Salomon, and Mark A Wainberg, and Michael A Parniak
October 2004, Current HIV research,
Gadi Borkow, and Horacio Salomon, and Mark A Wainberg, and Michael A Parniak
December 1990, Science (New York, N.Y.),
Gadi Borkow, and Horacio Salomon, and Mark A Wainberg, and Michael A Parniak
March 2008, Current HIV research,
Gadi Borkow, and Horacio Salomon, and Mark A Wainberg, and Michael A Parniak
December 2004, Antimicrobial agents and chemotherapy,
Gadi Borkow, and Horacio Salomon, and Mark A Wainberg, and Michael A Parniak
June 2001, Proceedings of the National Academy of Sciences of the United States of America,
Gadi Borkow, and Horacio Salomon, and Mark A Wainberg, and Michael A Parniak
December 2004, The Journal of infectious diseases,
Gadi Borkow, and Horacio Salomon, and Mark A Wainberg, and Michael A Parniak
August 2019, Antimicrobial agents and chemotherapy,
Gadi Borkow, and Horacio Salomon, and Mark A Wainberg, and Michael A Parniak
January 1996, Biochemistry,
Gadi Borkow, and Horacio Salomon, and Mark A Wainberg, and Michael A Parniak
October 2000, AIDS research and human retroviruses,
Copied contents to your clipboard!